Compare Entegris Inc (ENTG) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Pfizer Inc — how do they compare? Entegris Inc trades at $165 (market cap $24.78B), while Pfizer Inc trades at $28.18 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 6.4× Entegris Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Pfizer Inc for 158 Days on average.
| ENTG | PFE | |
|---|---|---|
Market Cap | $24.78B | $158.56B |
Volume | 2,648,320 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $184.00 | $29.02 |
52-Week Low | $68.80 | $23.67 |
Typical Hold Time | 41 Days | 158 Days |
Enterprise Value | $27.99B | $210.06B |
Dividend Yield | 0.25% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $164.22, down 1.26% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results expected soon. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Analysts maintain a strong buy consensus with a $182.43 price target, indicating potential upside.
The outlook for ENTG is positive, driven by AI-related semiconductor demand and operational improvements. Key risks include high valuation multiples and exposure to semiconductor cycle volatility. Institutional accumulation and recent patent defenses support confidence, but investors should monitor execution against earnings expectations and industry capital spending trends.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
